ATE502675T1 - Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin - Google Patents

Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin

Info

Publication number
ATE502675T1
ATE502675T1 AT07822140T AT07822140T ATE502675T1 AT E502675 T1 ATE502675 T1 AT E502675T1 AT 07822140 T AT07822140 T AT 07822140T AT 07822140 T AT07822140 T AT 07822140T AT E502675 T1 ATE502675 T1 AT E502675T1
Authority
AT
Austria
Prior art keywords
compounds
strengthen
medicine
application
ampa receptor
Prior art date
Application number
AT07822140T
Other languages
German (de)
English (en)
Inventor
Daniel Bradley
Wai Chan
Kevin Thewlis
Simon Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621967A external-priority patent/GB0621967D0/en
Priority claimed from GB0717262A external-priority patent/GB0717262D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE502675T1 publication Critical patent/ATE502675T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT07822140T 2006-11-03 2007-11-01 Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin ATE502675T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621967A GB0621967D0 (en) 2006-11-03 2006-11-03 Compounds
GB0717262A GB0717262D0 (en) 2007-09-05 2007-09-05 Compounds
PCT/EP2007/061794 WO2008053031A1 (en) 2006-11-03 2007-11-01 Compounds which potentiate ampa receptor and uses thereof in medicine

Publications (1)

Publication Number Publication Date
ATE502675T1 true ATE502675T1 (de) 2011-04-15

Family

ID=39099804

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07822140T ATE502675T1 (de) 2006-11-03 2007-11-01 Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin

Country Status (6)

Country Link
US (1) US20100137276A1 (enExample)
EP (1) EP2086643B1 (enExample)
JP (1) JP2010508328A (enExample)
AT (1) ATE502675T1 (enExample)
DE (1) DE602007013450D1 (enExample)
WO (1) WO2008053031A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0711088D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
US9493484B2 (en) 2012-02-08 2016-11-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
KR20170141767A (ko) 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 벤즈이미다졸론 및 벤조티아졸론 화합물 및 ampa 수용체 조절제로서의 이들의 용도
BR122023023802A2 (pt) 2015-04-29 2023-12-26 Janssen Pharmaceutica Nv Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem
BR112017023200A2 (pt) 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
BR112017023038A2 (pt) 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) * 2018-03-01 2018-04-18 Univ Of Sussex Compounds
WO2025231416A1 (en) * 2024-05-03 2025-11-06 Rapport Therapeutics, Inc. Methods of use of ampa receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159479B1 (es) 1999-10-25 2002-05-01 Menarini Lab Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
BRPI0514191A (pt) 2004-08-09 2008-06-03 Glaxo Group Ltd compostos que potencializam o receptor glutamato e seus usos em medicina

Also Published As

Publication number Publication date
JP2010508328A (ja) 2010-03-18
WO2008053031A1 (en) 2008-05-08
US20100137276A1 (en) 2010-06-03
EP2086643B1 (en) 2011-03-23
DE602007013450D1 (de) 2011-05-05
EP2086643A1 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
DE602007013450D1 (de) Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
CY1119248T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
SE0402735D0 (sv) Novel compounds
MX393395B (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
NZ595738A (en) Benzimidazole-piperidine-cyclohexane derivatives which have activity at M1 receptor and their uses in medicine
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
ATE526341T1 (de) Makrozyklische verbindungen als antivirale mittel
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2009005603A (es) Compuestos de urea policiclicos antibacterianos.
DE602004006166D1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
WO2022261240A3 (en) Dimethoxyphenylalkylamine activators of serotonin receptors
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
CY1112683T1 (el) Υποκατεστημενες καρβοξαμιδες ν-φαινυλ-διπυρρολιδινης και θεραπευτικες χρησεις τους
MX2009013501A (es) Compuestos piperidinicos y sus usos.
DE602008004540D1 (de) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3-yl)acetamidderivate und verwandte verbindungen als antipilzmittel
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
AR050208A1 (es) Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
TW200736189A (en) Indene derivatives, their preparation and use as medicaments

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties